Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility.
Ninety-eight females with congenital adrenal hyperplasia due to a defect in either the 21-hydroxylase or the 11 beta-hydroxylase enzyme were evaluated to determine the effects of glucocorticoid treatment on growth, pubertal development, and fertility. When treatment was begun prior to one year of age, mean final height was 157.4 +/- 7.3 com, well within the normal adult female range, and significantly (p less than 0.001) greater than the mean final height of 150.9 +/- 4.3 cm found in untreated patients. The mean age of menarche in patients treated prior to the age of six years was 13.8 +/- 3.7 years which is significantly (p less than 0.01) delayed compared to that in the normal population of the United States. However, 92% of patients with menstrual delay had inadequate suppression  of adrenal androgens and urinary excretion of 17 ketosteroids larger than 7.0 mg/24hours. The increased production of adrenal androgens was the result of poor compliance or an insufficient prescribed dose of glucocorticoids. The fertility rate in patients first treated between six and 20 years of age was 64%. The excretion of urinary 17 KS at the  time of pregnancy was 2.5 to 5.3 mg/24 hours. All of the patients who delivered term infants required delivery by cesarean section because of cephalopelvic disproportion. The major problems encountered in the management of adolescent patients were patient noncompliance and physician failure to increase the glucocorticoid dose as the patient's body size increased.
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects; D001940:Breast / Q000254:growth & development; D002648:Child; D002675:Child, Preschool; D003348:Cortisone / Q000494:pharmacology / Q000627:therapeutic use; D003900:Desoxycorticosterone / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000187:drug effects; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology / Q000627:therapeutic use; D007223:Infant; D008572:Menarche / Q000187:drug effects; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011627:Puberty / Q000187:drug effects; D012741:Sexual Maturation / Q000187:drug effects; D013250:Steroid Hydroxylases / Q000172:deficiency; D013997:Time Factors
D015068:17-Ketosteroids; D005938:Glucocorticoids; D003900:Desoxycorticosterone; D013250:Steroid Hydroxylases; D003348:Cortisone; D011241:Prednisone; D006854:Hydrocortisone